US2024074989A1PendingUtilityA1
Actinic keratosis treatment
Est. expiryDec 31, 2040(~14.4 yrs left)· nominal 20-yr term from priority
A61K 31/11A61P 17/00A61K 31/121A61K 31/095A61P 35/00A61P 17/12
49
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A compound of formula (I) R—S—CH 2 —CO—CF 3 (I) wherein R is a C 10-24 unsaturated hydrocarbon group comprising at least 4 non-conjugated double bonds; or a salt thereof; for use in the treatment of squamous cell carcinoma or actinic keratosis.
Claims
exact text as granted — not AI-modified1 - 8 . (canceled)
9 . A method of treating actinic keratosis or squamous cell carcinoma comprising administering to an animal, an effective amount of a compound of formula (I):
R—S—CH 2 —CO—CF 3 (I)
wherein R is a C 10-24 unsaturated hydrocarbon group comprising at least 4 non-conjugated double bonds; or a salt thereof.
10 . (canceled)
11 . The method of claim 9 , wherein the animal is a mammal.
12 . The method of claim 11 , wherein the mammal is a human.
13 . The method of claim 9 , wherein said hydrocarbon group R has 5 to 7 double bonds.
14 . The method of claim 9 , wherein in said hydrocarbon group R, no double bond is conjugated with the carbonyl group.
15 . The method of claim 9 , wherein in said hydrocarbon group R all double bonds are in the cis configuration or wherein in said hydrocarbon group all double bonds are in the cis configuration except the double bond nearest the carbonyl.
16 . The method of claim 9 , wherein the R group comprises 17 to 19 carbon atoms.
17 . The method of claim 9 , where the compound of formula (I) is
18 . The method of claim 9 , wherein the compound is administered orally or topically.Join the waitlist — get patent alerts
Track US2024074989A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.